Register for our free email digests:
Alaric DeArment
Reporter

Latest From Alaric DeArment
Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
Sarepta Charges Ahead With DMD Gene Therapy Despite Setback
The company plans to start its Phase III trial of SRP-9001 in the middle of this year, with a potential readout by the end of 2022.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
GSK Antibody Appears Effective In Older COVID-19 Patients
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.